Back
NeoGenomics, Inc. 10K Form
Buy
56
NEO
NeoGenomics, Inc.
Last Price:
$11.85
Seasonality Move:
55.32%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | NEO/NeoGenomics, Inc. Quarterly |
| 2024-02-20 | 10K | NEO/NeoGenomics, Inc. Annual |
| 2023-11-06 | 10Q | NEO/NeoGenomics, Inc. Quarterly |
| 2023-08-08 | 10Q | NEO/NeoGenomics, Inc. Quarterly |
| 2023-05-09 | 10Q | NEO/NeoGenomics, Inc. Quarterly |
| 2023-02-24 | 10K | NEO/NeoGenomics, Inc. Annual |
Receive NEO News And Ratings
See the #1 stock for the next 7 days that we like better than NEO
NEO Financial Statistics
Sales & Book Value
| Annual Sales: | $660.6M |
|---|---|
| Cash Flow: | $570K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $6.50 |
| Price / Book: | 1.83 |
Profitability
| EPS (TTM): | -0.88770 |
|---|---|
| Net Income (TTM): | $-113.5M |
| Gross Margin: | $256.7M |
| Return on Equity: | -12.92% |
| Return on Assets: | -7.42% |
NeoGenomics, Inc. Earnings Forecast
Key NeoGenomics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 27 years for NEO is 38.85%.
-
The Selling, General & Administrative Expenses for NEO have been equal to 52.14% of Gross Profit Margin.
-
The Research & Development expenses have been 4.72% of Revenue.
-
The Net Earning history of NEO is -11.92% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 12 years.
NeoGenomics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Health Care Providers & Services |
| Sector: | Health Care |
| Current Symbol: | NEO |
| CUSIP: | 64049M |
| Website: | neogenomics.com |
Debt
| Debt-to-Equity Ratio: | 0.49 |
|---|---|
| Current Ratio: | 3.91 |
| Quick Ratio: | 3.26 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 66.08 |
NEO Technical Analysis vs Fundamental Analysis
Buy
56
NeoGenomics, Inc. (NEO)
is a Buy
Is NeoGenomics, Inc. a Buy or a Sell?
-
NeoGenomics, Inc. stock is rated a BuyThe current NeoGenomics, Inc. [NEO] share price is $11.84. The Score for NEO is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.